# Herpes Zoster Non-Live Recombinant Vaccine
## Biological Page

<table>
<thead>
<tr>
<th>Section 7:</th>
<th>Biological Product Information</th>
<th>Standard #: 07.215</th>
</tr>
</thead>
<tbody>
<tr>
<td>Created by:</td>
<td>Province-wide Immunization Program Standards and Quality</td>
<td></td>
</tr>
<tr>
<td>Approved by:</td>
<td>Province-wide Immunization Program Standards and Quality</td>
<td></td>
</tr>
<tr>
<td>Approval Date:</td>
<td>September 1, 2021</td>
<td>Revised:</td>
</tr>
</tbody>
</table>

### SHINGRIX®

**Manufacturer**
GlaxoSmithKline Inc.

**Biological Classification**
Non-live recombinant, AS01B adjuvanted

**Indications for Provincially Funded Vaccine**
Solid Organ Transplant recipients 18 years of age and older (pre and post solid organ transplant).
*See Immunization of Adult Solid Organ Transplant Candidates and Recipients for additional information.*

**Serology**
See Immunization of Adult Solid Organ Transplant Candidates and Recipients for additional information regarding serology recommendations.

**Schedule**

**Primary Series:**
- Dose 1: Day 0
- Dose 2: Two to six months later

**Notes:**
- Persons with active HZ should not be immunized with HZ vaccine. Vaccine may be considered at least one year after an episode of HZ disease.
- SHINGRIX® is recommended for those that have received Zostavax® prior to transplant. An interval of one year is recommended between live attenuated Herpes Zoster (Zostavax®) and SHINGRIX®.

**Preferred Use**
N/A

**Dose**
0.5 mL

**Route**
Intramuscular Injection

**Contraindications/Precautions**

**Contraindications:**
- Known severe hypersensitivity to any component of the vaccine.
- Anaphylaxis to a previous dose of the vaccine.

**Precautions:**
- SHINGRIX® is not indicated for prevention of primary varicella infection or for the treatment of herpes zoster (HZ) or postherpetic neuralgia (PHN).
- There are limited data available on the use of SHINGRIX® in immunocompromised adults 50 years of age or older.

**Possible Reactions**

**Common:**
- Pain, redness, itching and swelling at the injection site
- Fever, chills
- Fatigue, malaise
- Headache, myalgia
- Nausea, vomiting, diarrhea, abdominal pain

**Rare:**
- Allergic reactions
- Anaphylaxis
- As with any immunization, unexpected or unusual side effects can occur. Refer to product monograph for more detailed information.
<table>
<thead>
<tr>
<th><strong>SHINGRIX®</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnancy</strong></td>
<td>There are no data on the use of SHINGRIX® in pregnant women, therefore use with caution.</td>
</tr>
<tr>
<td><strong>Lactation</strong></td>
<td>There are no data on the use of SHINGRIX® in breastfeeding women, therefore use with caution.</td>
</tr>
</tbody>
</table>
| **Composition** | After reconstitution, one dose (0.5mL) contains:  
- 50 mcg Varicella Zoster Virus (VZV) glycoprotein E (gE)  
- 50 mcg *Quillaja saponaria* Molina fraction 21 (QS-21)  
- 50 mcg 3-O-desacyl-4'-monophosphoryl lipid A (MPL)  
Additional excipients - powder (gE):  
- dipotassium phosphate  
- polysorbate 80  
- sodium dihydrogen phosphate dihydrate  
- sucrose  
Additional excipients - suspension (AS01B adjuvant system)  
- cholesterol  
- dioleoyl phosphatidylcholine  
- disodium phosphate anhydrous  
- potassium dihydrogen phosphate  
- sodium chloride  
- water for injection |
| **Blood/Blood Products** | Contains no human blood/blood products |
| **Bovine/Porcine Products** | Contains no bovine or porcine products |
| **Latex** | There is no latex in the vaccine or vaccine packaging |
| **Interchangeability** | SHINGRIX® is the only non-live licensed vaccine for the prevention of HZ (shingles) in Canada. |
| **Administration with Other Products** |  
- SHINGRIX® may be administered concomitantly with, or at any time before or after, other inactivated vaccines or live vaccines protecting against a different disease.  
- The vaccines should be administered at different injection sites. |
| **Appearance** |  
- The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.  
- The lyophilized powder is white. |
| **Storage** |  
- Store both lyophilized vial and adjuvant solution at +2°C to +8°C.  
- Protect from light. |
| **Preparation** |  
- Shingrix® must be reconstituted prior to administration.  
- Withdraw the entire contents of the vial containing the adjuvant suspension into a sterile syringe.  
- Add the entire contents of the syringe into the vial containing the lyophilized powder.  
- Shake gently until the lyophilized powder is completely dissolved. |
| **Vaccine Code** | Var-SI |
| **Antigen Code** | VZ |
| **Licensed for** |  
- Individuals 50 years of age and older.  
- **Off-license use:** Solid Organ Transplant recipients between 18 years and 49 years of age. |
| **Program Notes:** |  
- 2021 September 1: Implemented for solid organ transplant recipients 18 years of age and older. |
| **Related Resources:** |  
- Herpes Zoster (Shingles) Vaccine – Shingrix (VAR-SI) Information Sheet |
### References:


